# US 2026/0061078 A1 · Adenoviral-Based In Situ Delivery of Bispecific T Cell Engagers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061078 A1
- Document ID: US20260061078A1
- Status: Published application
- Kind: A1
- Application number: 19/105,122
- Filed: 2023-08-30
- Published: 2026-03-05
- Earliest claimed: 2022-08-31
- Assignees: UniversitäT ZüRich
- Applicants: Universität Zürich
- Inventors: Jonas KOLIBIUS; Patrick Christian FREITAG; Andreas PLÜCKTHUN; Ronja WIEBOLDT; Heinz LÄUBLI
- Web page: https://patentgrep.com/patent/US20260061078A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 35/761: Adenovirus
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- C07K 16/32: against translation products of oncogenes
- C12N 15/86: Viral vectors
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are recombinant non-oncolytic viruses, for example adenoviruses, that encode bispecific T cell engagers (BiTE's). These BiTE's can be expressed at any desired site of the human body. The non-oncolytic viruses are able to direct expression of the BiTE's in situ, i.e. directly at the site at which the BiTE's exert their action. The non-oncolytic viruses are useful in the treatment of diseases such, as cancer.

## Claims

### Claim at position 1

1: A recombinant non-oncolytic virus comprising a bispecific T cell engager and a recombinant adapter molecule, wherein said recombinant adapter molecule comprises
a) a designed ankyrin repeat domain which binds to a target antigen exposed on the cell surface,
b) a designed ankyrin repeat domain which binds to the knob of the adenovirus, and
c) a trimerization domain.

### Claim at position 2 (depends on 1)

2: The non-oncolytic virus according to claim 1, wherein said bispecific T cell engager comprises
a) a first binding domain comprising a VH domain and a VL domain that bind to a T cell surface antigen, and
b) a second binding domain comprising a designed ankyrin repeat domain which binds to a target antigen exposed on the cell surface.

### Claim at position 3 (depends on 1)

3: The non-oncolytic virus according to claim 1, wherein said non-oncolytic virus is an adenovirus.

### Claim at position 4 (depends on 1)

4: The non-oncolytic virus according to claim 1, wherein said bispecific T cell engager is encoded in the genome of the non-oncolytic virus.

### Claim at position 5 (depends on 1)

5: The non-oncolytic virus according to claim 1, wherein said trimerization domain is or is derived from the capsid protein SHP of lambdoid phage 21.

### Claim at position 6 (depends on 1)

6: The non-oncolytic virus according to claim 1, wherein said designed ankyrin repeat domain that binds to a knob of an adenovirus comprises the amino acid sequence of SEQ ID No. 2.

### Claim at position 7 (depends on 1)

7: The non-oncolytic virus according to claim 1, wherein said recombinant adapter molecule comprises from the N- to the C-terminus
a) said designed ankyrin repeat domain which binds to a target antigen exposed on the cell surface,
b) said designed ankyrin repeat domain which binds to the knob of the adenovirus, and
c) said trimerization domain.

### Claim at position 8 (depends on 2)

8: The non-oncolytic virus according to claim 2, wherein said first binding domain of said bispecific protein comprises a HCDR1 of SEQ ID No. 3, a HCDR2 of SEQ ID No. 4, a HCDR3 of SEQ ID No. 5, a LCDR1 of SEQ ID No. 6, a LCDR2 of SEQ ID No. 7 and a LCDR3 of SEQ ID No. 8.

### Claim at position 9 (depends on 2)

9: The non-oncolytic virus according to claim 2, wherein said target antigen bound by said second binding domain of said bispecific T cell engager and said target antigen exposed on the cell surface and bound by the designed ankyrin repeat domain of said recombinant adapter molecule are the same target antigen.

### Claim at position 10 (depends on 9)

10: The non-oncolytic virus according to claim 9, wherein said target antigen is HER2 (SEQ ID No. 12).

### Claim at position 11 (depends on 2)

11: The non-oncolytic virus according to claim 2, wherein said target antigen bound by said second binding domain of said bispecific T cell engager and said target antigen exposed on the cell surface and bound by the designed ankyrin repeat domain of said recombinant adapter molecule are different target antigens.

### Claim at position 12 (depends on 2)

12: The non-oncolytic virus according to claim 2, wherein said designed ankyrin repeat domain which binds to a target antigen exposed on the cell surface comprises SEQ ID No. 13.

### Claim at position 13 (depends on 1)

13: A method for treatment of cancer in a patient, said method comprising administering to the patient the non-oncolytic virus of claim 1.

### Claim at position 14 (depends on 1)

14: An eukaryotic cell containing a non-oncolytic virus according to claim 1 and/or expressing a bispecific T cell engager encoded on the genome of said non-oncolytic virus.

### Claim at position 15 (depends on 2)

15: The non-oncolytic virus according to claim 2 wherein said T cell surface antigen is CD3.

### Claim at position 16 (depends on 3)

16: The non-oncolytic virus of claim 3 wherein the adenovirus is of serotype 5 and/or is a gutless or helper-dependent adenovirus.

### Claim at position 17 (depends on 5)

17: The non-oncolytic virus of claim 5 wherein said trimerization domain comprises the amino acid sequence of SEQ ID No. 1.
